Cardiosonic Announces Completion of the TIVUS I Trial and the Start of the TIVUS II Trial

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel--(BUSINESS WIRE)--Cardiosonic Ltd., a privately held company developing innovative and proprietary technology in the field of renal denervation (RDN) for the treatment of hypertension, announced the completion of patient enrollment in its first-in-man (FIM) TIVUS I clinical study. The study is designed to collect data on the safety and performance of the TIVUS™ System, a unique therapeutic ultrasound catheter system for the treatment of hypertension by renal denervation (RDN).

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC